February 27, 2008 - Boston Scientific Corp. said the FDA approved three products in its Cardiac Rhythm Management business, including the CONFIENT implantable cardioverter defibrillator (ICD), the LIVIAN cardiac resynchronization therapy defibrillator (CRT-D) and an upgraded LATITUDE Patient Management System.
The CONFIENT ICD reportedly features an enhanced AV (atrial ventricular) Search Hysteresis designed to reduce unnecessary right ventricular pacing. The device is equipped with wireless capability designed to save physicians time during implant by allowing device programming during wound closure and eliminating the need for the programming wand in the sterile field. Wireless capability also saves time at follow-up visits by offering device interrogations that can be three times faster than the company’s wanded telemetry, said Boston Scientific.
The LIVIAN CRT-D reportedly enables physicians to provide patients with individualized therapy using SmartDelay technology which enables physicians to tailor individualized pacing therapies for their patients. The CRT-DA also used the Bi-V Trigger with ventricular rate regulation designed to help physicians manage heart failure patients with frequent atrial arrhythmias.
The upgraded LATITUDE Patient Management System reportedly has enhanced remote monitoring capabilities that include a new alert in the CONFIENT ICD that notifies physicians if a patient’s percentage of right ventricular pacing increases above a programmable threshold, and a new alert notifies physicians if a patient’s percentage of biventricular pacing falls below a programmable threshold.
Both the CONFIENT ICD and LIVIAN CRT-D are designed to allow physicians to manage their patients wirelessly on the LATITUDE Patient Management System.
For more information: bostonscientific.com
September 05, 2024 
